HomeCompareBNYN vs PFE

BNYN vs PFE: Dividend Comparison 2026

BNYN yields 1052631.58% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BNYN wins by $7.963497503125679e+36M in total portfolio value
10 years
BNYN
BNYN
● Live price
1052631.58%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.963497503125679e+36M
Annual income
$7,962,009,567,722,528,000,000,000,000,000,000,000,000,000.00
Full BNYN calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — BNYN vs PFE

📍 BNYN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBNYNPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BNYN + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BNYN pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BNYN
Annual income on $10K today (after 15% tax)
$89,473,684.21/yr
After 10yr DRIP, annual income (after tax)
$6,767,708,132,564,148,000,000,000,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, BNYN beats the other by $6,767,708,132,564,148,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BNYN + PFE for your $10,000?

BNYN: 50%PFE: 50%
100% PFE50/50100% BNYN
Portfolio after 10yr
$3.9817487515628397e+36M
Annual income
$3,981,004,783,861,264,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

BNYN
No analyst data
Altman Z
-11.4
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BNYN buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBNYNPFE
Forward yield1052631.58%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$7.963497503125679e+36M$49.6K
Annual income after 10y$7,962,009,567,722,528,000,000,000,000,000,000,000,000,000.00$26,258.71
Total dividends collected$7.963400145668761e+36M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BNYN vs PFE ($10,000, DRIP)

YearBNYN PortfolioBNYN Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$105,273,858$105,263,157.89$9,153$693.39+$105.26MBNYN
2$1,035,762,991,230$1,035,650,348,202.03$8,593$849.25+$1035762.98MBNYN
3$9,524,008,370,109,804$9,522,900,103,709,188.00$8,336$1,066.78+$9524008370.10MBNYN
4$81,846,272,920,654,280,000$81,836,082,231,698,260,000.00$8,437$1,384.80+$81846272920654.27MBNYN
5$657,352,099,039,416,200,000,000$657,264,523,527,391,100,000,000.00$9,013$1,875.40+$657352099039416192.00MBNYN
6$4,934,208,226,426,849,000,000,000,000$4,933,504,859,680,876,000,000,000,000.00$10,306$2,680.72+$4.934208226426849e+21MBNYN
7$34,614,450,996,181,180,000,000,000,000,000$34,609,171,393,378,904,000,000,000,000,000.00$12,820$4,101.38+$3.461445099618118e+25MBNYN
8$226,943,778,760,972,850,000,000,000,000,000,000$226,906,741,298,406,850,000,000,000,000,000,000.00$17,673$6,826.70+$2.2694377876097286e+29MBNYN
9$1,390,593,834,719,905,300,000,000,000,000,000,000,000$1,390,351,004,876,631,000,000,000,000,000,000,000,000.00$27,543$12,591.86+$1.3905938347199052e+33MBNYN
10$7,963,497,503,125,679,000,000,000,000,000,000,000,000,000$7,962,009,567,722,528,000,000,000,000,000,000,000,000,000.00$49,560$26,258.71+$7.963497503125679e+36MBNYN

BNYN vs PFE: Complete Analysis 2026

BNYNStock

Banyan Corp., through its subsidiaries, engages in the franchising of chiropractic clinics in North America. It provides practice development training and assistance to chiropractors, as well as offers franchise support and related services to franchisees and licensees. The company also offers diagnostic testing services. Banyan Corporation provides nerve conduction velocity (NCV) testing to patients through health care professionals, such as doctors and chiropractors. The NCV testing measures the transmission of nerve impulses through the body, identifies problems in the nervous system, and enables to substantiate the cost of treatment to patients and their insurers. In addition, it manufactures and markets the VT3000, a nerve testing system for the diagnosis of neuropathies, which are diseases of the peripheral nerves and parts of the spine, as well as nerve irritation and other damage to the nervous system of a patient. The company was founded in 1978 and is based in Beverly Hills, California.

Full BNYN Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this BNYN vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BNYN vs SCHDBNYN vs JEPIBNYN vs OBNYN vs KOBNYN vs MAINBNYN vs JNJBNYN vs MRKBNYN vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.